Federal regulators at the FDA had no way to prioritize the conduct and completion of certain trials over others, or to steer enrollment toward higher-value studies. Researchers at the NIH could use their funding mechanisms to support high-priority studies, but they had limited ability to direct academic sites to prioritize enrollment in some clinical trials over others.
